MARKET

NVCN

NVCN

Neovasc Inc
NASDAQ
6.77
+0.21
+3.20%
Closed 16:00 09/30 EDT
OPEN
6.79
PREV CLOSE
6.56
HIGH
6.79
LOW
6.66
VOLUME
6.12K
TURNOVER
25.56K
52 WEEK HIGH
20.58
52 WEEK LOW
4.585
MARKET CAP
18.57M
P/E (TTM)
-0.5597
1D
5D
1M
3M
1Y
5Y
Neovasc puts further development of its Tiara transcatheter treatment on hold
Neovasc (NASDAQ:NVCN) on Tuesday said it would put on hold further d...
Seekingalpha · 09/20 18:48
BRIEF-Neovasc Provides Corporate Update Following Clinical Data Release
BRIEF-Neovasc Provides Corporate Update Following Clinical Data Release
Reuters · 09/20 14:04
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
VANCOUVER and MINNEAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in...
GlobeNewswire · 09/16 13:00
BRIEF-Neovasc Comments On New ICD-10-CM Diagnosis Codes For Refractory Angina
BRIEF-Neovasc Comments On New ICD-10-CM Diagnosis Codes For Refractory Angina
Reuters · 09/15 14:14
Neovasc Announces Key Events at TCT 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced its participation and presence at the Transcatheter Cardiovascular Therapeut...
Newsfile · 09/08 13:05
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
VANCOUVER and MINNEAPOLIS, Aug. 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investmen...
GlobeNewswire · 08/30 13:05
BRIEF-Neovasc Announces Second Quarter Financial Results And Provides Corporate Update
BRIEF-Neovasc Announces Second Quarter Financial Results And Provides Corporate Update
Reuters · 08/11 21:10
Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13M
Neovasc press release (<span class="ticker-hover-wrapper"...
Seekingalpha · 08/11 20:12
More
About NVCN
Neovasc Inc. is a Canada-based specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.

Webull offers kinds of Neovasc Inc stock information, including NASDAQ:NVCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCN stock methods without spending real money on the virtual paper trading platform.